How do standard folic acid (FA) and active 5-methyltetrahydrofolate (5-MTHF) compare when dosed equimolarly in pregnancy?
Synthetic FA must be reduced and remethylated—MTHFR is a key step—to yield circulating 5-MTHF. MTHFR variants are relatively common in Asian populations; direct 5-MTHF supplementation can bypass that bottleneck in theory. Head-to-head, adequately powered RCTs in pregnant women have been limited.
A 2026 double-blind randomized controlled trial in Clinical Nutrition ESPEN (Indonesia) enrolled women at 9–14 weeks’ gestation (110 randomized; 96 completed). Arms: FA 600 μg/day vs glucosamine salt 5-MTHF 1,100 μg/day (near-identical molar dose) for 12 weeks. Outcomes: RBC folate (long-term stores), plasma 5-MTHF, plasma homocysteine, and unmetabolized folic acid (UMFA), with BMI-stratified analyses (normal weight vs overweight).
Key findings
→ RBC folate & homocysteine: both arms improved status; no significant between-group difference for long-term stores or homocysteine reduction. → Plasma 5-MTHF: larger rise with 5-MTHF—borderline significant overall (p=0.055); the signal was clearer in normal-BMI women; overweight subgroups differed less. → UMFA: median increase on FA was about twice that on 5-MTHF, but the difference did not reach statistical significance (sample-size limited); the gap looked more pronounced among overweight participants.
Boundaries that matter This trial measured biomarkers, not neural-tube-defect (NTD) prevention. Enrollment at 9–14 weeks misses the periconceptional NTD window—so it cannot rank formulations on clinical NTD outcomes. MTHFR genotype was not assayed. UMFA’s clinical risk remains debated; absolute UMFA levels here were relatively low. Southeast Asian cohort—useful reference for Chinese practice, not a one-to-one transplant.
Takeaway for industry & clinic At equimolar dose, FA and 5-MTHF look broadly similar for long-term folate stores and homocysteine. 5-MTHF trends toward higher plasma active folate and lower UMFA accumulation—plausible rationale for MTHFR-risk or preference-driven substitution. FA remains a cost-effective foundation. Choice can integrate genotype (when available), BMI response patterns, and economics—not a single “winner” headline.
Educational summary of published science only—not obstetric or supplementation advice.
#Folate #5MTHF #FolicAcid #PrenatalNutrition #MTHFR #ClinicalNutrition #RCT #IngredientScience #Nutraceuticals #NugenePharma
